Anaptysbio (ANAB) Other Non-Current Liabilities (2016 - 2026)

Anaptysbio (ANAB) has 10 years of Other Non-Current Liabilities data on file, last reported at $263.7 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non-Current Liabilities fell 20.17% year-over-year to $263.7 million; the trailing twelve-month figure through Mar 2026 stood at $263.7 million (down 20.17% YoY), and the FY2025 full-year result was $276.5 million, down 21.76% from the prior year.
• Other Non-Current Liabilities for Q1 2026 stood at $263.7 million, down from $276.5 million in the prior quarter.
• Across five years, Other Non-Current Liabilities topped out at $362.0 million in Q2 2024 and bottomed at $35.0 million in Q3 2022.
• The 5-year median for Other Non-Current Liabilities is $310.2 million (2024), against an average of $294.5 million.
• The widest annual swing landed in 2023, when Other Non-Current Liabilities soared 789.35%; it then decreased 21.76% in 2025.
• A 5-year view of Other Non-Current Liabilities shows it stood at $304.4 million in 2022, then grew by 2.1% to $310.8 million in 2023, then increased by 13.71% to $353.4 million in 2024, then declined by 21.76% to $276.5 million in 2025, then dropped by 4.62% to $263.7 million in 2026.
• The last three Other Non-Current Liabilities figures came in at $263.7 million (Q1 2026), $276.5 million (Q4 2025), and $331.8 million (Q3 2025), per Business Quant data.

Peer Comparison